U.S. officials are urging telecommunication companies to boost network security following a Chinese hacking operation that gave officials in Beijing access to the private texts and phone conversations of Americans
A U.S. Senate subcommittee has held a hearing to question the growing use of airline fees to charge passengers for things like early boarding and better seats
U.S. stock indexes rose to more records after tech companies talked up how much artificial intelligence is boosting their results
Proteins are made of chains of amino acids, and a basic tenet of biology is that the sequence of amino acids determines how a protein folds into a 3D shape which, in turn, dictates the protein’s function. But another tenet of biology is that rules are meant to be broken.
The effort to develop psychedelic therapies took a hit earlier this month when the FDA rejected Lykos Therapeutics’ MDMA-assisted therapy, a blow that was quickly followed by the retraction of three Lykos research papers and the slashing of 75% of the biotech’s workforce.
Foreign-made drugs are often unavailable in Japan due to the country’s approval process, which requires clinical trial data from Japanese patients. To address this issue, known as “drug loss,” Japanese technology company Fujitsu is partnering with American start-up Paradigm Health to attract global clinical trials to the island nation.
Illumina has secured an FDA approval to bring its pan-cancer tissue profiling test to U.S. shores.
Repare Therapeutics is laying off a quarter of its workforce as the oncology biotech scales back its preclinical work to focus on more advanced candidates such as a synthetic lethal drug handed back by Roche earlier this year.
Amid a yearslong clinical trial decline in the U.K., a new public-private partnership has emerged in efforts to reinvigorate the country’s pharmaceutical testing prowess.
Following the announcement of a large layoff round in April and a major restructuring initiative unveiled earlier this month, Genentech is sending more jobs to the chopping block.
Weekly Market Review – December 28, 2024
Edgewise’s stock jumps 50% on the back of safety data for potential heart disease rival to Camzyos
In 2 papers, researchers describe potential new neurodegenerative disease treatment approach
Aligos’ MASH prospect slashes liver fat in phase 2, but stock drops anyway
Vanda receives FDA rejection, issues fiery response against ‘conclusory’ refusal
Jury rules for Axonics in Medtronic’s long-running neuromodulation patent lawsuit
Achilles drops cell therapy program, braces for layoffs after missing ‘commercial viability’ goals
Basilea scores $268M BARDA funding deal to work on antifungals, antibiotics
From ‘science fiction to reality’: New George Church-founded biotech raises $75M for cell therapy platform
How the Stock Market Defied Expectations Again This Year, by the Numbers
